NEW YORK (GenomeWeb News) - The Center for Molecular Medicine will use Xceed Molecular’s Ziplex gene expression system as part of a strategic collaboration, Xceed said today.
Xceed said that CMM is the first partner under its newly launched Strategic Collaborator program, in which customers can use or access Xceed’s Ziplex gene expression system, gene expression services, or expression arrays “at little or no cost in return for a commitment for future publication, access to biomarker content, or assistance with product development or services.”
CMM, based in Grand Rapids, Mich., is a joint venture between Spectrum Health and Van Andel Institute that seeks to develop technologies of use to diagnostics and pharmaceutical companies interested in diseases that are caused at the molecular level.
Xceed currently is developing genomic tests to run on its Ziplex system, and said it is using the collaboration program to develop clinical lab experience and gain access to results from “real-world” research.
The program is “an integral part” of Xceed’s goal to gain new assays for its pipeline of Signature Chips, which will be available as catalog products or through its Expression Services, the company said.
Financial terms of the agreement were not released.